Cancer News and Research

Latest Cancer News and Research

BioSense Technologies' Z-Sense Differential Impedance Sensing diagnostic system rapidly identifies drug susceptibility

BioSense Technologies, a pioneer in the development of diagnostic systems for rapid drug susceptibility testing, announced today that it presented key scientific findings at the National Foundation for Infection Disease 2010 Annual Conference on Antimicrobial Resistance, held in Bethesda, MD in early February.

19 Mar 2010

FDA drafts new rules for testing, approving drug cocktails; Public-private partnership for TB treatment development launched

The FDA is drafting new guidelines for testing and approving multidrug cocktails for life-threatening diseases, the Wall Street Journal reports. "Many diseases, such as AIDS, tuberculosis and cancer, require multidrug combinations. Such drug cocktails can prevent the development of drug resistance, because the microbe or cancer cell needs to undergo more mutations to escape several drugs than to escape just one. By attacking the disease in different ways, drug combinations also improve the chances of therapeutic benefit," the newspaper reports (Schoofs, 3/18).

19 Mar 2010

Bionovo granted additional grace period for regaining compliance with NASDAQ's minimum bid requirement

Bionovo, Inc. today announced that on March 16, 2010, the Company received a letter from NASDAQ stating that the Company has been granted an additional 180 day grace period, until September 13, 2010, to regain compliance with the minimum bid price of $1.00 required for continued listing on the NASDAQ Capital Market.

19 Mar 2010

Kaiser Permanente study: Snapshot of the prevalence of extreme obesity in younger children

Extreme obesity is affecting more children at younger ages, with 12 percent of black teenage girls, 11.2 percent of Hispanic teenage boys, 7.3 percent of boys and 5.5 percent of girls now classified as extremely obese, according to a Kaiser Permanente study of 710,949 children and teens that appears online in the Journal of Pediatrics.

19 Mar 2010

Interfering with dickkopf 1 protein may help in controlling inflammatory bowel diseases

Signals released by immune cells during a bout of inflammatory bowel disease interfere with intestinal cells' ability to regenerate. Yet people with inflammatory bowel diseases have a significantly higher risk of developing colon cancer: a hyper-activation of growth in those same intestinal cells.

19 Mar 2010

GSK's 2009 Corporate Responsibility Report published online

In its 2009 Corporate Responsibility Report published online today, GSK reiterated its commitment to running its business responsibly and to making the company more responsive, more flexible and more open to the expectations of society.

19 Mar 2010

Rates of breast cancer occurrences in Asian women rising among specific ethnic groups

Research scientists from the Cancer Prevention Institute of California (CPIC) released the results of a study of breast cancer in Asian women which examined their cancer rates by ethnicity, age and immigrant status. The findings challenge the notion that breast cancer rates are uniformly low across the population of Asian women and indicate rising rates of occurrences in specific ethnic groups. CPIC scientists studied Asian populations in California, the state with the largest and most diverse Asian population in the U.S.

19 Mar 2010

Phase 1B clinical study initiated to evaluate safety and efficacy of PMX-60056

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has initiated a Phase 1B clinical study to evaluate the safety and efficacy of PMX-60056 in reversing the anticoagulant activity of low molecule weight heparin (LMWH).

19 Mar 2010

ASCO Scientific Program 2010: Provectus Pharmaceuticals' Phase 2 data on PV-10 accepted for presentation

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data from its Phase 2 study of PV-10 for metastatic melanoma has been accepted for presentation at the 2010 American Society of Clinical Oncology (ASCO) Scientific Program to be held on June 4 – 8, 2010 in Chicago, Illinois.

19 Mar 2010

Survey unveils impact of gene regulation on human health

Researchers are only beginning to understand how individual variation in gene regulation can have a lasting impact on one's health and susceptibility to certain diseases. Now, an ambitious survey of the human genome has identified differences in the binding of master regulators called transcription factors to DNA that affect how genes are expressed in different people.

19 Mar 2010

Proteacel acquires exclusive rights to PORE technology from Moffitt Cancer Center

Moffitt Cancer Center and Proteacel LLC announced today that they have entered a licensing agreement under which Proteacel has acquired the exclusive rights to the PORE™ technology for delivery of genes into cells.

18 Mar 2010

Solos Endoscopy secures U.S. Trademark for MammoView name

Solos Endoscopy, Inc. is pleased to announce the Company has secured the U.S. Trademark for the MammoView® name. The MamoView® Breast Endoscopy System offers a state-of-the-art endoscopic technology for detecting early stage breast cancer. The Company's Breast Endoscopy System employs advanced micro endoscopes and optical technology to give physicians sharp, clear images of the milk ducts, where the majority of breast cancers arise.

18 Mar 2010

Novelos Therapeutics Phase 3 trial of NOV-002 in advanced NSCLC fails to meet primary and secondary endpoints

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that primary and secondary endpoints were not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) with its lead product, NOV-002, in combination with first-line chemotherapy.

18 Mar 2010

ZIOPHARM Oncology reports fourth quarter net income of $1.0M against loss last year

ZIOPHARM Oncology, Inc., a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, announced today its financial results for the fourth quarter and full year 2009, and the filing of its Annual Report on Form 10-K with the Securities and Exchange Commission.

18 Mar 2010

Manitoba government: AMD drug Lucentis will be funded through centralized vision program

Manitobans with wet age-related macular degeneration (AMD) received a dose of good news. The Manitoba government announced that Lucentis (ranibizumab injection) will soon be funded through a centralized vision program, effective June 1, 2010.

18 Mar 2010

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.

18 Mar 2010

Risk of hereditary form of bowel cancer: New preparation of omega-3 holds hope

A new preparation of an omega-3 polyunsaturated fatty acid found naturally in fish, offers hope for thousands of patients at risk of developing an inherited form of bowel cancer, a new study shows.

18 Mar 2010

MR-guided ablation therapy may hold promise for treatment of prostate cancer recurrences

The first known patient cases using magnetic resonance-guided heat (laser interstitial thermal therapy) or cold (cryoablation) to treat prostate cancer recurrence after surgical removal of the prostate gland were presented by physicians at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa. Many of these patients have also failed salvage radiation treatment and are often presented with limited therapeutic options. MR-guided focal therapy offers a new treatment choice for patients because of the improved detection of early prostate cancer recurrences best seen with MR imaging.

18 Mar 2010

Canadian Cancer Society launches daffodil pin campaign to fight back against cancer

The Canadian Cancer Society, BC and Yukon, is stepping up the fight by announcing today the launch of an inaugural daffodil pin - a badge of courage - as part of its annual Daffodil month campaign when canvassers go door-to-door.

18 Mar 2010

Concord Medical Services Holdings reports 24.3% increase in total net revenues for fourth-quarter 2009

Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the fourth quarter and fiscal year ended December 31, 2009(1), and the appointment of Dr. Hongbin Cai as an independent board member.

18 Mar 2010

Cancer News and Research

Latest Cancer News and Research

BioSense Technologies' Z-Sense Differential Impedance Sensing diagnostic system rapidly identifies drug susceptibility

FDA drafts new rules for testing, approving drug cocktails; Public-private partnership for TB treatment development launched

Bionovo granted additional grace period for regaining compliance with NASDAQ's minimum bid requirement

Kaiser Permanente study: Snapshot of the prevalence of extreme obesity in younger children

Interfering with dickkopf 1 protein may help in controlling inflammatory bowel diseases

GSK's 2009 Corporate Responsibility Report published online

Rates of breast cancer occurrences in Asian women rising among specific ethnic groups

Phase 1B clinical study initiated to evaluate safety and efficacy of PMX-60056

ASCO Scientific Program 2010: Provectus Pharmaceuticals' Phase 2 data on PV-10 accepted for presentation

Survey unveils impact of gene regulation on human health

Proteacel acquires exclusive rights to PORE technology from Moffitt Cancer Center

Solos Endoscopy secures U.S. Trademark for MammoView name

Novelos Therapeutics Phase 3 trial of NOV-002 in advanced NSCLC fails to meet primary and secondary endpoints

ZIOPHARM Oncology reports fourth quarter net income of $1.0M against loss last year

Manitoba government: AMD drug Lucentis will be funded through centralized vision program

USPTO allows Regulus Therapeutics' claims covering methods of antagonizing miR-181a for regulating immune response

Risk of hereditary form of bowel cancer: New preparation of omega-3 holds hope

MR-guided ablation therapy may hold promise for treatment of prostate cancer recurrences

Canadian Cancer Society launches daffodil pin campaign to fight back against cancer

Concord Medical Services Holdings reports 24.3% increase in total net revenues for fourth-quarter 2009

Understanding the DNA Damage Response in Innate Immunity eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in